Latest Financial Impact News

Gold Corporation, trading as The Perth Mint (ASX:GCB), reported a record $100.19 million profit before tax for 2025-26 and recommended its largest-ever dividend to the Western Australian Government. The result was powered by extraordinary precious-metals demand and prices, but the company’s own budget points to a much leaner year ahead.

CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.

Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.

Medibank delivered higher FY26 operating profit, underlying earnings and dividends, while its health services arm posted strong growth after the Better Medical acquisition. The annual report also leaves investors weighing cybercrime litigation, capital flexibility and the pace of Medibank Health’s expansion.

Adisyn says the USPTO has allowed its third US patent application, extending its graphene deposition claims from metallic surfaces to non-metallic semiconductor materials. The allowed claims also include low-temperature processing and in-process quality checks, although commercial adoption remains unconfirmed.

Anson Resources has secured approval for an estimated US$212 million post-performance tax credit tied to its Green River Lithium Project in Utah. The benefit could materially improve the project’s projected economics, but it will only be realised if the project proceeds, generates tax revenue and meets the scheme’s conditions.

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.

Red Sky Energy has started drilling Yarrow 5 in South Australia, the second well in a three-well development program operated by Santos. The well is expected to reach 2,775 metres by 14 September, with a further re-entry planned before first gas from Yarrow North 1 is targeted for early 2027.

The FDA has agreed that EBR Systems’ WiSE cardiac pacing system does not require a field corrective action or recall following a February cybersecurity incident. The device maker says it has found no evidence of any impact on the safety or performance of fielded systems, while remediation work continues.

Income Asset Management Group has attributed a late director interest notice to an administrative oversight and miscommunication, after ASX questioned whether disclosure rules may have been breached. IAM says it has reiterated its director reporting process and will strengthen controls if required.

Boresight Ltd’s US subsidiary has landed a US$383,275 purchase order from a repeat North American military customer, tripling previous drone orders and expanding its footprint in counter-drone training.